



СРПСКИ АРХИВ
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
SERBIAN ARCHIVES
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

+381 11 4092 776, Fax: +381 11 3348 653

E-mail: office@srpskiarhiv.rs, Web address: www.srpskiarhiv.rs

Paper Accepted*

ISSN Online 2406-0895

Review Article / Прегледни рад

Andrea Tinelli^{1,2,†}, Radmila Sparić^{3,4}

Myoma pseudocapsule – a biological and surgical structure to respect during myomectomy

Псеудокапсула миома – биолошка и хируршка структура коју треба поштовати током миомектомије

¹Vito Fazzi Hospital, Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy, Department of Obstetrics and Gynecology, Lecce, Italy;

²Moscow Institute of Physics and Technology (State University), Faculty of Biological and Medical Physics, Phystech BioMed School, Laboratory of Human Physiology, Dolgoprudny, Moscow Region, Russia;

³Clinical Centre of Serbia, Clinic for Gynecology and Obstetrics, Belgrade, Serbia;

⁴University of Belgrade, Faculty of Medicine, Belgrade, Serbia

Received: July 20, 2019

Revised: December 27 2019

Accepted: February 11, 2020

Online First: February 22, 2020

DOI: <https://doi.org/10.2298/SARH190720014T>

***Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

†**Correspondence to:**

Andrea TINELLI

Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy, Department of Obstetrics and Gynecology, Vito Fazzi Hospital, Lecce 73100, Italy

E-mail: andreatinelli@gmail.com

Myoma pseudocapsule – a biological and surgical structure to respect during myomectomy

Псеудокапсула миома – биолошка и хируршка структура коју треба поштовати током миомектомије

SUMMARY

Uterine fibroids affect almost one in two patients, causing many pelvic problems and requiring pharmacologic and surgical treatment. For many years, the importance of the fibroid was emphasized as uterine pathology, without focusing on the complex myometrial biology peripheral to fibroid. Moreover, the traditional surgical technique in fibroid removal has not been investigated for years. In recent years, on the contrary, morphological, neuroendocrine and anatomical studies have demonstrated the importance of a biological and surgical structure surrounding myoma, rich in neurotransmitters and neurofibres, the myoma pseudocapsule. This structure is formed in the womb peripheral to fibroid onset, it separates the fibroid from the myometrium and acts as a tissue regenerator after removal of the fibroid from the uterus. The translation of scientific research on pseudocapsules into surgical practice has allowed us to identify new techniques of myomectomy, removing the myoma inside the pseudocapsule and promoting the pseudocapsules sparing surgery. All this to favor the subsequent biological process of uterine scarring and healing, by activating the neurotransmitters and neurofibres present in the myometrial fovea. The correct healing after fibroid removing restores the uterine anatomy, with a positive impact on subsequent reproductive function, reducing problems related to the muscle scar.

Keywords: myoma pseudocapsule; myomectomy; neurovascular bundle; reproductive surgery; pregnancy; fertility

САЖЕТАК

Миоми материце се јављају код готово сваке друге болеснице, узрокују бројне интрапелвичне тегобе и захтевају фармаколошко или хируршко лечење. Дуги низ година, значај миома је посматран као болест материце, без фокусирања на комплексну биологију миометријума који их окружује. Уз то, традиционална хируршка техника уклањања миома није истраживана годинама. Насупрот томе, у новије време, морфолошке, неуроендокрине и анатомске студије су показале значај биолошке и хируршке структуре која окружује миом, богате неуротрансмитерима и нервним влакнима, односно псеудокапсуле миома. Ова структура се формира у материци периферно од миома, одваја миом од миометријума и функционише као регенератор ткива након уклањања миома из материце. Пренос научних истраживања псеудокапсула у хируршку праксу омогућио је настанак нових техника миомектомије, које подразумевају уклањање миома унутар псеудокапсуле и промовисање поштедних операција у односу на псеудокапсулу. Све ово погодује накнадним биолошким процесима оживљавања и зарастања материце, активацијом неуротрансмитера и нервних влакана присутних у миометријалној ложи миома. Правилно зарастање након уклањања миома успоставља анатомију материце, са позитвним утицајем на каснију репродуктивну функцију, смањујући компликације повезане са ожиљком миометријума.

Кључне речи: псеудокапсула миома; миомектомија; неуроваскуларна петелјка; репродуктивна хирургија; трудноћа; фертилитет

INTRODUCTION

Uterine myomas, leiomyomas or fibroids are the most common pathology in female genital organs, most of them are asymptomatic, but they can cause severe symptoms [1]. The prevalence of uterine fibroids is ranging from 5.4% to 77% [2]. Fibroids negatively affect female reproductive function, as they are recognized as an important cause of infertility. Moreover, women affected by fibroids are at higher risk for complications during pregnancy, labor, and delivery [3]. Fibroids are preferentially treated by surgery, by vaginal, laparoscopic, laparotomic or hysteroscopic approach [4, 5, 6].

Currently, minimally invasive techniques based on biologically reasoned myomectomy allow the preservation of the myoma pseudocapsule, in order to spare the muscular and fibro-

neurovascular myometrial fibers, ensuring the complete and bloodless removal of the myoma [7, 8].

PHYSIOLOGY OF UTERINE MUSCLE REPAIR

Myometrial scar after myomectomy requires a correct and physiological healing. The healing process, once the fibroid is enucleated, is one of the fundamental steps that restore uterine reproductive function. Nevertheless, the muscle damage itself may promote the signaling activities to trigger regeneration of the myometrium. The synthesis and release of signaling molecules, initiated by neurotransmitters and neurofibres, after the cellular damage, can prompt itself the cell activation, inducing muscle regeneration and healing [9]. After the muscle damage, the biological sequence “injury-repair-regeneration” leads to complete functional recovery during the days or weeks after the initial injury [10].

A fundamental process in the regeneration of a damaged muscle is the revascularization of the injured muscular tissue. The neoangiogenic network in the myometrial fovea (where the fibroid was located) is the first mark of tissue repair, as a necessity for the later morphological and functional healing. New capillaries grow from the surviving stems of the blood vessels into the center of the myometrial fovea; the neoangiogenesis in the damaged myometrium provides a sufficient supply of oxygen, improving aerobic energy metabolism for the muscular tissue repair [11]. In such regenerative process, the neuropeptides and neurotransmitters have an significant role in wound healing. Moreover, there is proof that the nervous system and its neurotransmitters, such as neuropeptide Y (NPY), Substance P (SP), Vasoactive Intestinal Peptide (VIP), Oxytocin, Vasopressin (VP), growth hormone-releasing hormone (GHRH), protein gene product 9.5 (PGP 9.5) and calcitonin gene-related peptide (CGRP) play a crucial role in mediating inflammation and healing processes [9, 12, 13]. Among these neurotransmitters, it has been demonstrated a slight distribution of oxytocin neurofibers into the uterus, with their high presence into the cervico-isthmic area [14].

Analyzing the biology of the myometrial scar after myomectomy, the spared neuropeptides enhance the correct myometrial healing at hysterotomic site and most of the above-mentioned neuropeptides have been found in the fibroid pseudocapsule, as a neurovascular bundle surrounding fibroid [14–17]. Until today, it has not been possible to clarify if the pseudocapsule vasculature network could be or sustained by mechanical and

inflammatory effects of fibroid on myometrium, or produced by a sort of “neoplastic-type” neoangiogenesis, due to the myoma growth or even to a muscle and tissue healing process [18].

In human uterus, obstacles in attaining serial specimens of hysterotomic scar after myomectomy are the main problems of biological and surgical investigations. Thus, the post-caesarean section and post-myomectomy remodeling processes in the womb are currently an unsolved puzzle. They can be monitored only by ultrasound (US) or magnetic resonance imaging (MRI) [19].

Healing of the wound is a vibrant process which involves neuromediators, neuropeptides, angiogenetic factors, blood cells, extracellular matrix and parenchymal cells. It follows three composite and coinciding phases: inflammation, tissue formation and remodeling [20]. In these phases, the intra pseudocapsule growth factors can be very useful in the enhancing the muscle repair process after myomectomy [21].

Anyway, the biogenesis of myoma pseudocapsule requires further investigations, either on the analysis of the hormonal and pharmacological effects of drugs on pseudocapsule, based on reducing fibroid growth without compromising pseudocapsule characteristics [22], or on the pre-operative therapy and the post-operative follow up, in order to preserve womb functionality, as much as possible [23].

THE “INTRACAPSULAR MYOMECTOMY”

The rationale for the fibroid removal starts with the preservation of its pseudocapsule (Figure 1.), the neurovascular bundle which surrounds myoma itself [15, 16, 17]. This modern technique of removing fibroids was adapted from the urology, in which the removal of the prostate gland must occur with the conservation of the neurovascular bundle above it. Thus, concerning the significance of the prostatic capsule sparing and the physiological role of nerve-sparing techniques for prostatectomy, it was possible to translate it on the pseudocapsule sparing during myomectomy.

There are also some passages that can be borrowed from urology to gynecology during prostatectomy and myomectomy. During laparoscopic/robotic prostatectomy, if bleeding

occurs, insufflation pressure can be in the meanwhile increased and a local compression can be performed also by hemostatic gauze, directly on prostate neurovascular bundle (the source of bleeding). The same surgical passages can be repeated during laparoscopic myomectomy (Figure 2.), in case of bleeding. Then, the hemostasis by high wattage diathermocoagulation should be always avoided during dissection near the prostate neurovascular bundles, as it has been shown that it can be harmful to cavernous nerve function in the canine model, with an indirect damage of the pelvic nerves of sexual function after prostatectomy [18, 24].

Returning to the fibroid enucleation technique, the possibility to perform myomectomy by removing the myoma from its pseudocapsule, was called “intracapsular myomectomy” [16, 18, 19]. In this technique, fibroid is carried out, by surgeon, from its muscular fovea, by stretching and enucleating myoma directly from the adjacent myometrium, avoiding the damage of the adjacent fibromuscular skeleton, breaking up the fibrous bridges (Figure 3.) [4, 6, 25, 26]. As a general surgical recommendation, in robotic, laparoscopic, laparotomic, vaginal or hysteroscopic setting, the surgical enucleation of each fibroid needs to be gently performed always to enhance and to improve the successive myometrial healing, trying to correctly restore the uterine anatomy and biology [27, 28]. Thus, the myoma pseudocapsule neurovascular bundle needs to be preserved and spared during myomectomy, avoiding any damaging surgical maneuvers, such as extensive and high wattage diathermocoagulation or unnecessary tissue manipulation or muscular injury. This physiological surgical technique to remove fibroids largely respects the fibroid neurovascular bundle, and its neuropeptides and neurofibers, since the iatrogenic pseudocapsule damage may change the successive neurotransmitters function in muscle repair, thus impairing uterine healing [8, 18].

The operative consequences of an inappropriate myomectomy technique performed with pseudocapsule injuring may lead to: 1) a reduction in the number of neuropeptides and neurofibers at hysterotomic site, with a negative impact on physiological myometrial healing; 2) an increase of fibrotic process at hysterotomic site; 3) a insufficiency either of myometrial neurotransmission or of muscular impulse and contractility. All of these features can lead to an altered post-surgical uterine physiology, as well as to a reduced uterine musculature functionality. This process could be the main responsible of impaired healing with uncorrected myometrial functionality, with unfavorable effects on a subsequent pregnancy, including a possible dramatic uterine rupture [29, 30].

LAPAROTOMIC/LAPAROSCOPIC INTRACAPSULAR MYOMECTOMY

The laparotomic and laparoscopic intracapsular myomectomy techniques do not differ substantially, except for the major surgical benefit of laparoscopy in case of subserous and intramural fibroids. The principal benefits of the endoscopic approach are the significant reduction of perioperative operative blood loss, the lower requiring of analgetic drugs and the shorter hospitalization. Additionally, laparoscopic intracapsular myomectomy results in slightly enhanced short-term outcomes in terms of postoperative fever, myometrium scar hematoma formation, ileus and antibiotic treatment, in comparison to laparotomic surgery (Figure 4.). The laparoscopic myomectomy has a reduced blood loss for the haemostatic CO₂ pressure, a part the selective gentle coagulation of pseudocapsule vessels. The CO₂ insufflation can reduce blood loss during laparoscopy, as the increased intra-peritoneal pressure can lead to the occlusion of the small blood vessels and capillaries during myomectomy [30]. This effect, in combination with a combined with a fewer traumatic endoscopic micro-manipulations, could result in overall positive surgical results [2, 7, 25].

Once the visceral peritoneum is incised in the midline longitudinal plane, by monopolar scissors, by Harmonic scalpel, monopolar scissors or crochet needle electrode, the myoma pseudocapsule is easily recognized during dissection and then cut to expose the fibroid surface. The identification of the “cleavage plane” between fibroid and pseudocapsule is important for a correct intracapsular myomectomy, in order not to preserve muscular fibres and to selectively coagulate blood vessels of pseudocapsule. Atraumatic clamp or irrigator cannula should be used to gently dissect myoma from its pseudocapsule. Hemostasis of the small vessels bleeding can be selectively achieved by a low wattage bipolar clamps, Harmonic scalpel, hook electrode or monopolar scissors, always at low wattage (not more than 30 watts), to progressively expose the hidden part of the fibroid into uterus (the myometrial fovea), incorrectly called “the base of the myoma”, and the pseudocapsule fibrovascular bridges (selectively coagulated). This technique allows a complete minimally traumatic removal of the fibroid from its pseudocapsule, with a minimal blood loss and a pseudocapsule sparing.

HYSTEROSCOPIC INTRACAPSULAR MYOMECTOMY

The rise of hysteroscopic myomectomy in 1976 [31] represented a revolution in the treatment of submucous fibroids: It allowed the abandonment of the laparotomic approach, significantly improving patients' surgical outcomes. Nowadays, the hysteroscopic myomectomy represents the gold standard in treatment of submucous myomas [32]. Nevertheless, the submucous myomas treatment is probably the high risk hysteroscopic procedure than other, for potential complications it has, as cervix laceration, hemorrhage, uterine perforation or clinical intravasation syndrome [33, 34]. It is not easy to estimate the right frequency of the abovementioned complications as it is of high variability according to pathology characteristics, surgeon skills and employed technique [35].

Wamsteker [36] and Lasmar [37] investigated and assessed the characteristics of submucous fibroids able to influence surgical outcomes in hysteroscopic myomectomy. The treatment of intracavitary fibroids with an intramural extension of 50% or more has always been represented as a challenge for the hysteroscopic surgeons, as it is burdened by an increasing risk for intraoperative complications, sometimes requiring a multiple-step procedure [5, 36, 38]. Moreover, in cases of multiple myomas, the risk it is even higher.

Currently, resectoscopic slicing still is the most commonly used technique for treating submucous myomas, and probably for this reason, myomectomy represents the hysteroscopic procedure with a higher complication rate. Unfortunately, the classical slicing technique, even in expert hands, does not respect the pseudocapsule and the adjacent healthy myometrium. During the resection of the intramural component of myoma, the "pseudocapsular tissue" should be visualized all over the resected area. Sometimes, for fibroid dimension and bleeding it can be challenging to make a distinction between the myoma tissue, the pseudocapsule and the healthy myometrium. The problem is the direct action of electrical loop during the myoma slicing and the uncorrect dissection of the anatomical planes. The traditional technique altered the intrauterine anatomy and it is almost impossible to avoid the injury of the myometrial fibers, causing a direct (by cutting) and indirect (by thermal spreading) damage of the pseudocapsule and surrounding healthy myometrium. This fundamental issue is responsible for all the intraoperative complications during the hysteroscopic myomectomy. Moreover, the role of surgical trauma to the healthy myometrium during hysteroscopic surgery can lead to synechiae and adhesions formation [28, 39].

The ideal hysteroscopic myomectomy ideally should be performed in one surgical step, as safe and effective procedure, which is simple and well-tolerated [32]. In the last decades, several techniques have been proposed, in order to overcome the limits represented by the classical slicing for the treatment of the myometrial portion of submucous myomas [5]. The main objective of these techniques was the detachment of the intra-myometrial part of the fibroid, in order to enable the sliding from the myometrium into the uterine cavity. Some authors proposed the use of uterine contractions, induced by manual massage [40], drugs [41, 42] or changing intrauterine pressure [43]. A combination of multiple techniques and the US monitoring during myomectomy was also described [44, 45]. Authors proposed the detachment of intramural component of fibroids by electrical incision of the fibroconnectival bridges, anchoring myoma to the pseudocapsule [46].

A technique that allowed us to overcome the limits represented by the classical slicing was described in 1995, as the cold loop hysteroscopic myomectomy [46]. This method allowed to change the approach to the myoma, from the progressive reduction or electrical power using and its switching to a mechanical enucleation of the myoma from the pseudocapsule, by the physiological contraction of myometrium. It represented a revolution in the hysteroscopic treatment of submucous fibroids, since it distinguished the anatomical planes, respected the anatomical and functional integrity of the myometrium and of the pseudocapsule, while at the same time ensuring a safe and effective procedure. By the cold loop myomectomy, the fibroconnective bridges that anchor the myoma to its pseudocapsule are mechanically disconnected, enucleating the intramural component of fibroid, without any effect to the adjacent healthy myometrial tissue. Moreover, the cold loops are applied between myoma and pseudocapsule, allowing to avoid uterine perforation by electrical loop and injury to abdominal organs or vessels. Noteworthy, in case of perforation by cold loops, the damage induced can be considered as the same with a Hegar dilator [8].

Finally, the respect of the myometrium allows uterine contraction, facilitating the sliding of the intramural part of the fibroid in the uterine cavity and at the same time increases the free myometrial margin thickness [47]. The uterine contraction and the respect of the myometrial muscular fibers decreases the risk of bleeding and the absorption of the distension medium, enhancing the possibility to accomplish the treatment in a single operation [48].

The respect of the pseudocapsule promotes the myometrial better healing, avoiding scarring and reducing the intrauterine adhesions and dramatic complications, such as subsequent uterine rupture [5, 28, 49, 50].

CONCLUSION

The morphological and molecular investigation performed on fibroid pseudocapsule changed the current surgical and biological scenario of myomectomy, for their interesting scientific results. The discovery of the fibroneurovascular structure surrounding fibroid, rich in neuropeptides and neurotransmitters, translated the new concept of myomectomy in reproductive surgery and in fertility sparing procedures, even for giant fibroids and during pregnancy.

Many evidences on the presence of angiogenetic proprieties in few millimeters of biological structure, the pseudocapsule, underline the necessity to preserve it as much as possible while performing myomectomy, especially to preserve myometrial integrity nearby the fibroid site, indirectly enhancing myometrial healing after myomectomy, and for less surgical bleeding.

Intracapsular myomectomy should also enhance the post-operative adhesions reduction. In our opinion, the intracapsular myomectomy, with a pseudocapsule sparing by endoscopic “microsurgical” magnification, as a safe and feasible minimally invasive technique, should be reproduced in all myomectomies.

Conflict of interest: None declared.

REFERENCES

1. Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of Uterine Myomas: A Review. *Int J Fertil Steril*. 2016;9:424-35. doi: 10.22074/ijfs.2015.4599. PMID: 26985330
2. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. *Obstet Gynecol*. 2000;95:764-9. doi: 10.1016/S0029-7844(99)00605-5. PMID: 10775744
3. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. *Am Fam Physician*. 2007;75:1503-8. PMID: 17555142
4. Rolli R, Favilli A, Acanfora MM, Scuderi G, Di Renzo GC, Gerli S. Vaginal myomectomy is a safe and feasible procedure: a retrospective study of 46 cases. *J Obstet Gynaecol Res*. 2012;38:1201-5. doi:10.1111/j.1447-0756.2012.01852.x. PMID: 22563644
5. Tinelli A, Malvasi A, Hudelist G, Cavallotti C, Tsin DA, Schollmeyer T, et al. Laparoscopic intracapsular myomectomy: comparison of single versus multiple fibroids removal. An institutional experience. *J Laparoendosc Adv Surg Tech A*. 2010;20:705-11. doi:10.1089/lap.2010.0082. PMID: 20701546
6. Di Spiezio Sardo A, Mazzon I, Bramante S, Bettocchi S, Bifulco G, Guida M, et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. *Hum Reprod Update*. 2008;14:101-19. doi:10.1093/humupd/dmm041. PMID: 18063608
7. Falcone T, Parker WH. Surgical management of leiomyomas for fertility or uterine preservation. *Obstet Gynecol*. 2013;121:856-68. doi:10.1097/AOG.0b013e3182888478. PMID: 23635687
8. Mazzon I, Favilli A, Grasso M, Horvath S, Di Renzo GC, Gerli S. Is Cold Loop Hysteroscopic Myomectomy a Safe and Effective Technique for the Treatment of Submucous Myomas With Intramural Development? A Series of 1434 Surgical Procedures. *J Minim Invasive Gynecol*. 2015;22:792-8. doi:10.1016/j.jmig.2015.03.004. PMID: 25796220
9. Hanna KR, Katz AJ. An update on wound healing and the nervous system. *Ann Plast Surg*. 2011;67:49-52. doi:10.1097/SAP.0b013e31822284de. PMID: 21629046
10. Tidball JG. Mechanisms of muscle injury, repair, and regeneration. *Compr Physiol*. 2011;1:2029-62. doi:10.1002/cphy.c100092. PMID: 23733696
11. Järvinen TA, Järvinen TL, Kääriäinen M, Kalimo H, Järvinen M. Muscle injuries: biology and treatment. *Am J Sports Med*. 2005;33:745-64. doi:10.1177/0363546505274714. PMID: 15851777
12. Henderson J, Terenghi G, Ferguson MW. The reinnervation and revascularisation pattern of scarless murine fetal wounds. *J Anat*. 2011;218:660-7. doi:10.1111/j.1469-7580.2011.01366.x. PMID: 21434911
13. Gouin JP, Carter CS, Pournajafi-Nazarloo H, Glaser R, Malarkey WB, Loving TJ, et al. Marital behavior, oxytocin, vasopressin, and wound healing. *Psychoneuroendocrinology*. 2010;35:1082-90. doi:10.1016/j.psyneuen.2010.01.009. PMID: 20144509
14. Malvasi A, Cavallotti C, Nicolardi G, Pellegrino M, Vergara D, Greco M, et al. The opioid neuropeptides in uterine fibroid pseudocapsules: a putative association with cervical integrity in human reproduction. *Gynecol Endocrinol*. 2013;29:982-8. doi:10.3109/09513590.2013.824958. PMID: 23937196
15. Malvasi A, Tinelli A, Cavallotti C, Morroni M, Tsin DA, Nezhat C, et al. Distribution of substance P (SP) and vasoactive intestinal peptide (VIP) in pseudocapsules of uterine fibroids. *Peptides*. 2011;32:327-32. doi: 10.1016/j.peptides.2010.10.034. PMID: 21167238
16. Mettler L, Tinelli A, Hurst BS, Teigland CM, Sammur W, Dell'edera D, et al. Neurovascular bundle in fibroid pseudocapsule and its neuroendocrinologic implications. *Expert Rev Endocrinol Metab*. 2011;6:715-722. doi: 10.1586/eem.11.62. PMID: 30780878
17. Malvasi A, Cavallotti C, Nicolardi G, Pellegrino M, Dell'edera D, Vergara D, et al. NT, NPY and PGP 9.5 presence in myometrium and in fibroid pseudocapsule and their possible impact on muscular physiology. *Gynecol Endocrinol*. 2013;29:177-81. doi: 10.3109/09513590.2012.708803 PMID: 22849656
18. Tinelli A, Malvasi A, Hurst BS, Tsin DA, Davila F, Dominguez G, et al. Surgical management of neurovascular bundle in uterine fibroids pseudocapsule. *JSLs*. 2012;16:119-129. doi: 10.4293/108680812X13291597716302. PMID: 22906340

19. Tinelli A, Hurst S.B, Mettler L, Tsin DA, Pellegrino M, Nicolardi G, et al. Ultrasound evaluation of uterine healing after laparoscopic intracapsular myomectomy: an observational study. *Hum Reprod.* 2012; 27:2664–2670. doi: 10.1093/humrep/des212. PMID: 22698929.
20. Vikhareva Osser O, Valentin L. Risk factors for incomplete healing of the uterine incision after caesarean section. *BJOG.* 2010;117:1119-26. doi: 10.1111/j.1471-0528.2010.02631.x. PMID: 20604776
21. Di Tommaso S, Massari S, Malvasi A, Bozzetti MP, Tinelli A. Gene expression analysis reveals an angiogenic profile in uterine leiomyoma pseudocapsule. *Mol Hum Reprod.* 2013;19:380-7. doi: 10.1093/molehr/gat007. PMID: 23355533
22. De Falco M, Staibano S, Mascolo M, Mignongna C, Improda L, Ciociola F, et al. Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. *Eur J Obstet Gynecol Reprod Biol.* 2009;144:44-7. doi: 10.1016/j.ejogrb.2009.02.006. PMID: 19297072
23. Mavrelou D, Ben-Nagi J, Davies A, Lee C, Salim R, Jurkovic D. The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial. *Hum Reprod.* 2010;25:2264-9. doi: 10.1093/humrep/deq188. PMID: 20663795
24. Ong AM, Su LM, Varkarakis I, Inagaki T, Link RE, Bhayani SB, et al. Nerve sparing radical prostatectomy: effects of hemostatic energy sources on the recovery of cavernous nerve function in a canine model. *J Urol.* 2004;172:1318-22. doi: 10.1097/01.ju.0000139883.08934.86. PMID: 15371832
25. Zhao X, Zeng W, Chen L, Chen L, Du W, Yan X. Laparoscopic Myomectomy Using "Cold" Surgical Instruments for Uterine Corpus Leiomyoma: A Preliminary Report. *Cell Biochem Biophys.* 2015;72:141-6. doi: 10.1007/s12013-014-0425-3. PMID: 25490906
26. Pitter MC, Srouji SS, Gargiulo AR, Kardos L, Seshadri-Kreaden U, Hubert HB, et al. Fertility and Symptom Relief Following Robot-Assisted Laparoscopic Myomectomy. *Obstet Gynecol Int.* 2015;2015:967568. doi: 10.1155/2015/967568. PMID: 25969688
27. Closon F, Tulandi T. Uterine myomata: Organ-preserving surgery. *Best Pract Res Clin Obstet Gynaecol.* 2016;35:30-6. doi: 10.1016/j.bpobgyn.2015.09.005. PMID: 26542930
28. Mazzon I, Favilli A, Cocco P, Grasso M, Horvath S, Bini V, et al. Does cold loop hysteroscopic myomectomy reduce intrauterine adhesions? A retrospective study. *Fertil Steril.* 2014;101:294-298.e3. doi: 10.1016/j.fertnstert.2013.09.032. PMID: 24182410
29. Chao AS, Chang YL, Yang LY, Chao A, Chang WY, Su SY, et al. Laparoscopic uterine surgery as a risk factor for uterine rupture during pregnancy. *PLoS One.* 2018;13:e0197307. doi: 10.1371/journal.pone.0197307. PMID: 29787604
30. Tinelli A, Mettler L, Malvasi A, Hurst B, Catherino W, Mynbaev OA, et al. Impact of surgical approach on blood loss during intracapsular myomectomy. *Minim Invasive Ther Allied Technol.* 2014;23:87-95. doi:0.3109/13645706.2013.839951. PMID: 24044380
31. Neuwirth RS. A new technique for and additional experience with hysteroscopic resection of submucous fibroids. *Am J Obstet Gynecol.* 1978;131:91-4. doi: 10.1016/0002-9378(78)90481-7. PMID: 645789
32. Pakrashi T. New hysteroscopic techniques for submucosal uterine fibroids. *Curr Opin Obstet Gynecol.* 2014;26:308-13. doi: 10.1097/GCO.0000000000000076. PMID: 24950124
33. Howe RS. Third-trimester uterine rupture following hysteroscopic uterine perforation. *Obstet Gynecol.* 1993;81:827-9. PMID:8469487
34. Jedeikin R, Olsfanger D, Kessler I. Disseminated intravascular coagulopathy and adult respiratory distress syndrome: life-threatening complications of hysteroscopy. *Am J Obstet Gynecol.* 1990;162:44-5. doi: 10.1016/0002-9378(90)90817-q. PMID:1689110
35. Murakami T, Tamura M, Ozawa Y, Suzuki H, Terada Y, Okamura K. Safe techniques in surgery for hysteroscopic myomectomy. *J Obstet Gynaecol Res.* 2005;31:216-23. doi:10.1111/j.1447-0756.2005.00274.x. PMID: 15916657
36. Wamsteker K, Emanuel MH, de Kruif JH. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. *Obstet Gynecol.* 1993;82:736-40. PMID:8414318
37. Lasmar RB, Barrozo PR, Dias R, Oliveira MA. Submucous myomas: a new presurgical classification to evaluate the viability of hysteroscopic surgical treatment--preliminary report. *J Minim Invasive Gynecol.* 2005;12:308-11. doi:10.1016/j.jmig.2005.05.014. PMID: 16036188

38. Emanuel MH, Wamsteker K, Hart AA, Metz G, Lammes FB. Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding. *Obstet Gynecol.* 1999;93:743-8. PMID: 10912978
39. Deans R, Abbott J. Review of intrauterine adhesions. *J Minim Invasive Gynecol.* 2010;17:555-69. doi: 10.1016/j.jmig.2010.04.016. PMID: 20656564
40. Hallez JP. Single-stage total hysteroscopic myomectomies: indications, techniques, and results. *Fertil Steril.* 1995;63:703-8. doi: 10.1016/S0015-0282(16)57469-X. PMID: 7890051
41. Darwish A. Modified hysteroscopic myomectomy of large submucous fibroids. *Gynecol Obstet Invest.* 2003;56:192-6. doi:10.1159/000074451. PMID: 14576470
42. Murakami T, Hayasaka S, Terada Y, Yuki H, Tamura M, Yokomizo R, et al. Predicting outcome of one-step total hysteroscopic resection of sessile submucous myoma. *J Minim Invasive Gynecol.* 2008;15:74-7. doi: 10.1016/j.jmig.2007.08.597. PMID: 18262148
43. Bernard G, Darai E, Poncelet C, Benifla JL, Madelenat P. Fertility after hysteroscopic myomectomy: effect of intramural myomas associated. *Eur J Obstet Gynecol Reprod Biol.* 2000;88:85-90. doi: 10.1016/S0301-2115(99)00123-2. PMID: 10659923
44. Korkmazer E, Tekin B, Solak N. Ultrasound guidance during hysteroscopic myomectomy in G1 and G2 Submucous Myomas: for a safer one step surgery. *Eur J Obstet Gynecol Reprod Biol.* 2016;203:108-11. doi: 10.1016/j.ejogrb.2016.03.043. PMID: 27267872
45. Ludwin A, Ludwin I, Pityński K, et al. Transrectal ultrasound-guided hysteroscopic myomectomy of submucosal myomas with a varying degree of myometrial penetration. *J Minim Invasive Gynecol.* 2013;20:672-85. doi: 10.1016/j.jmig. PMID: 23850363
46. Litta P, Vasile C, Merlin F, Basta P, Basta A, Banas T, et al. A new technique of hysteroscopic myomectomy with enucleation in toto. *J Am Assoc Gynecol Laparosc.* 2003;10:263-70. doi: 10.1016/j.jmig.2013.05.001. PMID: 12732782
47. Casadio P, Youssef AM, Spagnolo E, Rizzo MA, Basta A, Banas T, et al. Should the myometrial free margin still be considered a limiting factor for hysteroscopic resection of submucous fibroids? A possible answer to an old question. *Fertil Steril.* 2011;95:1764-8.e1. doi:10.1016/j.fertnstert.2011.10.029. PMID: 21315334
48. Mazzon I, Favilli A, Grasso M, Horvath S, Bini V, Di Renzo GC, et al. Predicting success of single step hysteroscopic myomectomy: A single centre large cohort study of single myomas. *Int J Surg.* 2015;22:10-4. doi: 10.1016/j.ijssu.2015.07.714. PMID: 26277533
49. Tinelli A, Mynbaev OA, Sparic R, Vergara D, Di Tommaso S, Salzet M, et al. Angiogenesis and Vascularization of Uterine Leiomyoma: Clinical Value of Pseudocapsule Containing Peptides and Neurotransmitters. *Curr Protein Pept Sci.* 2017;18:129-139. doi: 10.2174/1389203717666160322150338. PMID: 27001060
50. Tinelli A, Malvasi A, Guido M, Tsin DA, Hudelist G, Hurst B, et al. Adhesion formation after intracapsular myomectomy with or without adhesion barrier. *Fertil Steril.* 2011;95:1780-5. doi: 10.1016/j.fertnstert.2010.12.049. PMID: 21256483




Figure 1. Hystology of myoma pseudocapsule




Figure 2. Laparoscopic intracapsular myomectomy



Figure 3. Macroscopic exposition of pseudocapsule




Figure 4. Laparotomic intracapsular myomectomy